A pioneering molecular diagnostics company focused on early detection of cancer. Our mission: Stop it before it starts!.
Current Status
We do have 12 commercially available that we sell through a LDT process (State level) and have ongoing R&D on new tests. We do our R&D relying heavily on the use of AI for efficiency and cost reasons. We received two Frost & Sullivan Awards for our Lena Q51 and Lena S1 tests.
Problem or Opportunity
There are 600,000 cancer fatalities in the USA annualy because cancer is diagnosed too late. Our diagnostics have demonstrated that they can diagnose up to 41 months prior to clinical symptoms. Early diagnostic saves lives 88% survival rate for stage 0 or 1 versus 20%
Solution (product or service)
Our Tests for Leukemia and lung cancer (NSCLC) that are based on liquid biopsy and use genetics to determine the exact status of patients. The tests are done on standard PCR equipment and provide results within 3 hours at a fraction of the cost of standard practice.
Business model
We are selling a service to various cancer centers. After receiving blood samples from patients we run the tests through a CLIA laboratory with who we do have an agreement with. The results are sent to hospitals. Payment comes through direct payment and via insurance (Medicare & private insurance) using existing CPT code.
